Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir

[1]  D. Greenblatt,et al.  Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir , 2006, Clinical pharmacology and therapeutics.

[2]  N. Wood,et al.  Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities , 2006, Journal of clinical pharmacology.

[3]  A. Takagi,et al.  Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. , 2005, Biological & pharmaceutical bulletin.

[4]  W. Haefeli,et al.  Opposite effects of short‐term and long‐term St John's wort intake on voriconazole pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[5]  C. Ernest,et al.  Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.

[6]  R. Labadie,et al.  Pharmacokinetic interaction between voriconazole and ritonavir at steady state in healthy subjects , 2005 .

[7]  B. Clotet,et al.  Steady-State Pharmacokinetics of a Double-Boosting Regimen of Saquinavir Soft Gel plus Lopinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Infected Adults , 2004, Antimicrobial Agents and Chemotherapy.

[8]  M. Nakashima,et al.  Pharmacokinetics of Voriconazole and Cytochrome p450 2C19 Genetic Status , 2004, Clinical pharmacology and therapeutics.

[9]  A. Groll,et al.  Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. , 2003, The Journal of antimicrobial chemotherapy.

[10]  N. Wood,et al.  No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. , 2003, British journal of clinical pharmacology.

[11]  N. Wood,et al.  Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. , 2003, British journal of clinical pharmacology.

[12]  N. Wood,et al.  Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. , 2003, British journal of clinical pharmacology.

[13]  N. Wood,et al.  Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. , 2003, British journal of clinical pharmacology.

[14]  D. Back,et al.  Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. , 2003, British journal of clinical pharmacology.

[15]  T. Kuijpers,et al.  Liver failure in a child receiving highly active antiretroviral therapy and voriconazole. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  M. Rinaldi,et al.  Development and Validation of a High-Performance Liquid Chromatography Assay for Voriconazole , 2003, Antimicrobial Agents and Chemotherapy.

[17]  D A Smith,et al.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[18]  N. Wood,et al.  Safety of voriconazole and dose individualization. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  M. Pai,et al.  Voriconazole inhibition of tacrolimus metabolism. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Greenblatt,et al.  Short‐Term Exposure to Low‐Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone , 2003, Journal of clinical pharmacology.

[21]  Nina Singh,et al.  Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver Microsomes , 2002, Antimicrobial Agents and Chemotherapy.

[22]  E. Thiel,et al.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Goldstein,et al.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.

[24]  D. Greenblatt,et al.  Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir , 2000, Journal of acquired immune deficiency syndromes.

[25]  D. Greenblatt,et al.  Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole , 2000, European Journal of Clinical Pharmacology.

[26]  J. Kuper,et al.  Drug Interactions of HIV Protease Inhibitors , 1999, Drug safety.

[27]  J. Leonard,et al.  Pharmacokinetic interaction between ritonavir and clarithromycin * , 1998, Clinical pharmacology and therapeutics.

[28]  P. Vouros,et al.  Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[29]  J. Leonard,et al.  The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin * , 1998, Clinical pharmacology and therapeutics.

[30]  S. Piscitelli,et al.  Protease inhibitors for the treatment of human immunodeficiency virus infection. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[31]  William D. Dupont,et al.  PS power and sample size program available for free on the internet , 1997 .

[32]  J. Leonard,et al.  Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects , 1997, Antimicrobial agents and chemotherapy.

[33]  A. D. Rodrigues,et al.  Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[34]  M. Huang,et al.  Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs , 2005, Clinical pharmacokinetics.

[35]  C. Ernest,et al.  Mechanism-Based Inactivation of CYP 3 A by HIV Protease Inhibitors , 2005 .

[36]  T. Walsh,et al.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. , 2004, Drugs.

[37]  T. Kaminuma,et al.  Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. , 2003, Drug metabolism and pharmacokinetics.

[38]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[39]  P. Vouros,et al.  OF THE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITORS INDINAVIR AND RITONAVIR BY HUMAN INTESTINAL MICROSOMES AND EXPRESSED CYTOCHROME P 4503 A 4 / 3 A 5 : MECHANISM-BASED INACTIVATION OF CYTOCHROME P 4503 A BY RITONAVIR , 1998 .